Our objective is to determine the combined utility of CA-125, MIF, OPN and PROL in distinguishing ovarian cancer serum samples from healthy controls and compare its usefulness to CA-125 alone as a single biomarker. Here, MUC16 is linked to ovarian carcinoma.